Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety‐five patients with R/R HL, who received BV in 20 centers from Greece, were an...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Hematol Oncol
Prif Awduron: Angelopoulou, Maria K., Vassilakopoulos, Theodoros P., Batsis, Ioannis, Sakellari, Ioanna, Gkirkas, Konstantinos, Pappa, Vasiliki, Giannoulia, Panagiota, Apostolidis, Ioannis, Apostolopoulos, Christos, Roussou, Paraskevi, Panayiotidis, Panayiotis, Dimou, Maria, Kyrtsonis, Marie‐Christine, Palassopoulou, Maria, Vassilopoulos, Georgios, Moschogiannis, Maria, Kalpadakis, Christina, Margaritis, Dimitrios, Spyridonidis, Alexander, Michalis, Eurydiki, Anargyrou, Konstantinos, Repousis, Panagiotis, Hatzimichael, Eleutheria, Bousiou, Zoi, Poulakidas, Elias, Grentzelias, Dimitrios, Harhalakis, Nikolaos, Pangalis, Gerassimos A., Anagnostopoulos, Achilles, Tsirigotis, Panagiotis
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2017
Pynciau:
Original Research Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5836920/
https://ncbi.nlm.nih.gov/pubmed/28219112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hon.2383
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg